Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05697211
Other study ID # ORION-HF
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date February 21, 2023
Est. completion date October 2024

Study information

Verified date March 2023
Source Hannover Medical School
Contact Johann Bauersachs, Prof. Dr.
Phone +49 511 532
Email Bauersachs.Johann@mh-hannover.de
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label, single arm, multicenter pilot-study to explore the safety, tolerability and efficacy of oral iron supplementation with ferric maltol in treating iron deficiency and anaemia in patients with heart failure.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date October 2024
Est. primary completion date September 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Men, women*, inter/diverse aged = 18 at day of inclusion 2. Signed written informed consent from patient prior to any study-related procedure and willingness to comply with treatment and follow-up procedures 3. Patients capable of understanding the investigational nature, potential risks and benefits of the clinical trial 4. Patients with chronic heart failure with an Left ventricular ejection fraction (LVEF)<50% (Heart failure with reduced ejection fraction (HFrEF), Heart failure with a mid-range ejection fraction (HFmrEF)) or patients with chronic heart failure with an EF=50% (HFpEF) and New York Heart Association functional class II-IV 5. 6 min walk distance >50 m 6. Mild-to-moderate anaemia and iron -deficiency as defined by a haemoglobin concentration =8 g/dl and <12 g/dl in females or =9 g/dl and <13 g/dl in males, and serum ferritin <100 µg/l, or 100-299 µg/l and transferrin saturation <20% at screening 7. *Women without childbearing potential defined as follows: - females before menarche (if applicable) - at least 6 weeks after surgical sterilization by bilateral tubal ligation or bilateral oophorectomy or - hysterectomy or uterine agenesis or - = 50 years and in postmenopausal state > 1 year or - < 50 years and in postmenopausal state > 1 year with serum Follicle stimulating hormone (FSH) > 40 IU/l and serum estrogen < 30 ng/l or a negative estrogen test, both at screening or *Women of childbearing potential: - who are practicing sexual abstinence (periodic abstinence and withdrawal are not acceptable) or - who have sexual relationships with female partners only and/or with sterile male partners or - who are sexually active with fertile male partner, have a negative pregnancy test during screening and agree to use reliable methods of contraception** from the time of screening until end of the clinical trial. - The following methods of contraception are acceptable): e.g. - progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action - male or female condom with or without spermicide - cap, diaphragm or sponge with spermicide Exclusion Criteria: 1. Active haematological disorders other than anaemia and/or iron -deficiency 2. Other medical condition that according to the investigator's assessment is causing or contributing to anaemia 3. Active malignancy or currently receiving chemotherapy or radiotherapy 4. Active infectious disease 5. Active bleeding 6. Severe renal insufficiency (glomerular filtration rate (GFR) < 20ml/min or requiring dialysis) 7. Severe liver injury as indicated by serum aminotransferases >3 x upper limit of normal or bilirubin levels >50 µmol/l 8. Ongoing oral or intravenous iron supplementation 9. Concomitant erythropoietin medication 10. Erythropoiesis stimulating agents (ESA), i.v. iron or blood transfusion administered in last 3 months and oral iron (>100 mg/day) in previous 4 weeks 11. Pregnancy or lactation period 12. Subject has received any investigational medication or any investigational devices within 30 days prior to the first dose of study medication or is actively participating in any investigational drug/ devices trial, or is scheduled to receive investigational drug/devices during the course of the study 13. Known or suspected hypersensitivity to any of the active substances or any excipients of the investigational medicinal product 14. Known haemochromatosis or other iron overload syndromes 15. Patients with severe, uncorrected valvular heart disease 16. Clinical evidence of Acute coronary syndrome (ACS), Transient ischaemic attack (TIA) or stroke within the last 30 days 17. Coronary artery bypass graft (CABG), Percutaneous transluminal coronary angioplasty (PTCA), cardiac device implant/resynchronisation therapy or major surgery leading to significant blood loss within last 30 days 18. Planned CABG, PTCA, cardiac device implant/resynchronisation therapy or major surgery 19. Anaemia due to reasons other than iron deficiency (e.g., haemoglobinopathy). Subjects with Vitamin B12 or folic acid deficiency who in the opinion of the Investigator are stable and asymptomatic will be permitted.

Study Design


Intervention

Drug:
Ferric maltol 30 mg (Feraccru®)
In this trial Feraccru® 30 mg hard capsules will be used. Each capsule contains 30 mg iron (as ferric maltol), 91.5 mg of lactose, 0.5 mg of Allura Red AC (E129) and 0.3 mg Sunset Yellow FCF (E110) as excipients with known effects.

Locations

Country Name City State
Germany Hannover Medical School, Department of Cardiology and Angiology Hannover Lower Saxony

Sponsors (2)

Lead Sponsor Collaborator
Hannover Medical School Norgine

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Other Incidence of treatment-emergent adverse events (AEs) To assess the safety and tolerability of oral ferric maltol in heart failure patients with iron deficiency and anaemia. up to Week 20
Other Incidence of Adverse Events Number of drop-outs due to AEs up to Week 20
Primary Change in haemoglobin level from baseline to week 16 baseline to week 16
Secondary Change in serum ferritin from baseline to week 16 baseline to week 16
Secondary Change in transferrin saturation from baseline to week 16 baseline to week 16
Secondary Change in soluble transferrin receptor 1 from baseline to week 16 baseline to week 16
Secondary Change in 6 min walking distance from baseline to week 16 baseline to week 16
Secondary Change in Health-related quality of life (HRQoL, measured by KCCQ-12) from baseline to week 16 KCCQ = Kansas City Cardiomyopathy Questionnaire
The KCCQ 12 is a health-related quality of life questionnaire to measure the disease-specific health status of patients with heart failure. It is a 12 item questionnaire that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge and quality of life. Scores are generated for each domain and scaled from 0 to 100, with 0 denoting the lowest reportable health status and 100 the highest reportable health status.
baseline to week 16
Secondary Change in serum N-terminal pro brain natriuretic peptide (NT-proBNP) from baseline to week 16 baseline to week 16
Secondary Change in echocardiographic markers of left ventricular function from baseline to week 16 measurement of left ventricular ejection fraction baseline to week 16
Secondary Change in echocardiographic markers of left ventricular function from baseline to week 16 measurement of left ventricular diameter baseline to week 16
Secondary Change in echocardiographic markers of left ventricular function from baseline to week 16 measurement of left ventricular end-systolic volume index baseline to week 16
Secondary Change in echocardiographic markers of left ventricular function from baseline to week 16 measurement of left ventricular end-diastolic volume index baseline to week 16
Secondary Change in echocardiographic markers of left ventricular function from baseline to week 16 measurement of left ventricular wall thickness baseline to week 16
Secondary Change in echocardiographic markers of left ventricular function from baseline to week 16 measurement of left atrial volume index baseline to week 16
Secondary Change in echocardiographic markers of left ventricular function from baseline to week 16 measurement of global longitudinal strain baseline to week 16
Secondary Change in echocardiographic marker of left ventricular function from baseline to week 16 measurement of marker of diastolic function (E/e') baseline to week 16
Secondary Change in echocardiographic markers of right ventricular function from baseline to week 16 measurement of right ventricular diameter baseline to week 16
Secondary Change in echocardiographic markers of right ventricular function from baseline to week 16 measurement of tricuspid annular plane systolic excursion baseline to week 16
Secondary Change in echocardiographic markers of right ventricular function from baseline to week 16 measurement of estimated systolic pulmonary arterial pressure baseline to week 16
Secondary Liver: Change in Albumin from baseline to week 16 baseline to week 16
Secondary Liver: Change in Alanine transaminase (ALT) from baseline to week 16 baseline to week 16
Secondary Liver: Change in Aspartate transaminase (AST) from baseline to week 16 baseline to week 16
Secondary Liver: Change in Bilirubin from baseline to week 16 baseline to week 16
Secondary Kidney: Change in Creatinine (+Glomerular filtration rate) from baseline to week 16 baseline to week 16
Secondary Change in New York Heart Association (NYHA) class from baseline to week 16 baseline to week 16
See also
  Status Clinical Trial Phase
Completed NCT04435574 - Lactoferrin for Treatment of Iron Deficiency Anemia. Phase 4
Not yet recruiting NCT05467319 - Ferric Derisomaltose/Iron Isomaltoside and Outcomes in the Recovery of Gynecologic Oncology ERAS Phase 3
Not yet recruiting NCT05050851 - Nutritional Parameters and Other Risk Factors Affecting Severity of Pneumonia in Children Under Five Years in Upper Egypt
Recruiting NCT04278651 - Early Antenatal Support for Iron Deficiency Anemia Phase 4
Recruiting NCT04626414 - Four-Way Crossover Study to Compare Ferric Maltol Capsules and Oral Suspension in Healthy Volunteers Phase 1
Withdrawn NCT03800446 - Validation of a Point-of-care Device Measuring Ferritin With Capillary Blood N/A
Recruiting NCT05304442 - IV Iron Trial for Anemia Related to Uterine Bleeding in Female Patients Presenting to the Emergency Department Phase 3
Enrolling by invitation NCT03897673 - Optimizing Benefits While Reducing Risks of Iron in Malaria-endemic Areas N/A
Completed NCT05047211 - Intravenous Iron vs. Oral Iron Supplementation for Postpartum Anemia Phase 4
Not yet recruiting NCT06061393 - Comparison Between Outcomes of Pregnant Women Treated With Ferinject vs. Venofer for Iron Deficiency Anemia Phase 4
Completed NCT05190263 - Quality Assurance on Anemia Management in Patients With Solid Tumors and Malignant Lymphoma
Completed NCT03318055 - Prevalence of Hyperglycemia and Anaemia in Elective Surgical Patients
Completed NCT04631679 - Investigation of the Wash-out Effect of Intravenous Iron by Cell Savers (WASH-OUT)
Recruiting NCT05225545 - Sucrosomial Iron vs. Oral Iron Sulfate for the Treatment of Iron Deficiency Anemia in Patients With Ulcerative Colitis Phase 3
Recruiting NCT03347513 - Eradication of H-pylori in Pregnancy and Its Effect on Iron Replacement Therapy? Phase 4
Recruiting NCT04708665 - Iron Deficiency Anemia and Non-iron Deficiency Anemia in Pregnancy in India
Completed NCT02404012 - Iron Supplement to Improve Iron Status Following Bariatric Surgery N/A
Completed NCT04137354 - Iron and Vitamin A in School Children N/A
Not yet recruiting NCT06096103 - A Clinical Study to Check the Safety and Effectiveness of Botanical Extract Standardized for Iron + Vitamin c and Botanical Extract Standardized for Iron in Adult Human Subjects With Anemia or Iron-deficiency Anemia N/A
Completed NCT03156712 - Iron Absorption From Iron-enriched Aspergillus Oryzae N/A